Second-line chemotherapy in gastric cancer following S-1 with CPT-11 chemotherapy performed as clinical trial

We previously conducted a phase I/II study of irinotecan (CPT-11) combined with S-1 as first-line chemotherapy for metastatic advanced gastric cancer. In the present study,second-line chemotherapy was given to 32 of 44 patients whose disease became refractory to this first-line treatment. Overall su...

Full description

Saved in:
Bibliographic Details
Published inGan to kagaku ryoho Vol. 34; no. 6; p. 875
Main Authors Inokuchi, Mikito, Yamashita, Toshiki, Yamada, Hiroyuki, Kojima, Kazuyuki, Sekita, Yoshihisa, Kawano, Tatsuyuki, Sugihara, Kenichi
Format Journal Article
LanguageJapanese
Published Japan 01.06.2007
Subjects
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Camptothecin - administration & dosage
Camptothecin - analogs & derivatives
Cisplatin - administration & dosage
Drug Administration Schedule
Drug Combinations
Female
Humans
Male
Middle Aged
Oxonic Acid - administration & dosage
Paclitaxel - administration & dosage
Retrospective Studies
Stomach Neoplasms - drug therapy
Stomach Neoplasms - mortality
Survival Rate
Tegafur - administration & dosage
Online AccessGet more information

Cover

More Information
Summary:We previously conducted a phase I/II study of irinotecan (CPT-11) combined with S-1 as first-line chemotherapy for metastatic advanced gastric cancer. In the present study,second-line chemotherapy was given to 32 of 44 patients whose disease became refractory to this first-line treatment. Overall survival time of the patients given second-line chemotherapy was significantly longer than that of patients not given such therapy (444 days vs. 230 days, p = 0.013). The response rate to second-line chemotherapy was 13% (4/32). Survival time of patients who responded to second-line chemotherapy was significantly longer than that of non-responders. Second-line chemotherapy may produce a better clinical response in patients who have progressive disease during first-line chemotherapy. Overall survival time and time to progression after second-line chemotherapy did not significantly differ between patients who received second-line chemotherapy regimens including S-1 and those who received regimens not including S-1.
ISSN:0385-0684